Why We Invested in Iterative Scopes (Computer Vision vs Cancer)

1 min read

Iterative Scopes is announcing shortly a large seed round and is one of the bets we are making through Tau Ventures, an AI-first seed fund in Silicon Valley. The company was incubated at MIT and impressed us with identifying (1) a strong need, (2) building an execution-focused team, and (3) creating a differentiated product. In our diligence we spoke to various experts including the Head of Gastroenterology at Johns Hopkins and the Chief Innovation Officer of Mount Sinai who is a GI, validating for us the need and the solution. This post is focused specifically on the company but also…...

This article is free to read

Login to read the full article


OR
Amit Garg I have been in Silicon Valley for 20 years -- at Samsung NEXT Ventures, running my own startup (as of May 2019 a series D that has raised $120M and valued at $450M), at Norwest Ventures, and doing product and analytics at Google. My academic training is BS in computer science and MS in biomedical informatics, both from Stanford, and MBA from Harvard. I speak natively 3 languages, live carbon-neutral, am a 70.3 Ironman finisher, and have built a hospital in rural India serving 100,000 people.

Schedule a DDIChat with Amit Garg

app.ddichat.com/experts/amit-garg

Follow DDI

Gain Access to Expert Views

We won't send you spam. Unsubscribe at any time.